8-K: QT Imaging Reports Strong Q2 Revenue, Unveils AI Cloud

QT Imaging Holdings, Inc. announced robust second-quarter 2025 financial results with significant revenue growth and strategic advancements, including the launch of its QTI Cloud Platform and progress towards a Nasdaq uplisting.

Summary

• Generated record revenue of $3.7 million in Q2 2025, representing 113% year-over-year growth and 31% sequential quarter-over-quarter growth.
• Shipped eight QT Imaging Breast Acoustic CT scanners in Q2 2025, with two more shipped in July, aligning with 2025 annual projections.
• Unveiled the 'QTI Cloud Platform,' a strategic initiative to transform breast health through imaging intelligence via a tiered Software as a Service (SaaS) delivery model, expected to provide new recurring revenues.
• Strengthened financial position with $700,000 in net proceeds from two Private Investment in Public Entity (PIPE) investments, including $500,000 from Board members.
• Addressed and removed warrant liability through amendments to the Lynrock Lake and Yorkville Warrant Agreements on June 11, 2025, resulting in equity-classified warrants for accounting purposes.
• Reported a gross margin of 50% in Q2 2025, a slight decline from 51% in Q2 2024 due to inventory cost variability.
• Total operating expenses improved by 7% to $2.9 million in Q2 2025 compared to $3.1 million in Q2 2024.
• Net loss for Q2 2025 was $4.0 million, which includes a $2.8 million change in the fair value of warrant liability and $0.2 million change in the fair value of earnout liability.
• Non-GAAP Adjusted EBITDA improved to $(0.8) million for Q2 2025, compared to $(2.1) million for Q2 2024.
• Net cash used in operating activities increased to $1.5 million in Q2 2025 from $1.0 million in Q2 2024.
• Cash balance was $2.0 million as of June 30, 2025, increasing to $4.3 million as of August 6, 2025, after collections for scanner shipments.
• Reiterated 2025 revenue target of $18 million (40 scanners) and 2026 revenue target of $27 million (60 scanners) based on committed orders with NXC Imaging.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and is on track with its annual projections. Significant strategic moves, including the launch of an AI-powered cloud platform and efforts to uplist to Nasdaq, indicate positive future potential. The reclassification of warrant liabilities strengthens the balance sheet. While net loss increased, it was largely due to non-cash accounting adjustments, and Adjusted EBITDA improved. The increased cash burn from operations is a minor concern, but the post-quarter cash position is stronger.

Positives

• Achieved record revenue of $3.7 million in Q2 2025, demonstrating 113% year-over-year growth and 31% sequential growth, aligning with annual projections.
• Successfully shipped eight QT Imaging Breast Acoustic CT scanners in Q2 and two more in July, building a foundation for broader adoption.
• Unveiled the 'QTI Cloud Platform' strategic initiative, signaling a transformation into a precision imaging AI company with expected new recurring SaaS revenues.
• Strengthened the balance sheet by addressing and removing warrant liability through amendments to the Lynrock Lake and Yorkville Warrant Agreements, reclassifying them to equity.
• Improved Non-GAAP Adjusted EBITDA to $(0.8) million in Q2 2025 from $(2.1) million in Q2 2024.
• Reduced total operating expenses by 7% to $2.9 million in Q2 2025.
• Secured $700,000 in net proceeds from PIPE investments, enhancing financial position.
• Appointed Elaine Iuanow, MD, as Chief Medical Officer and Kim Du as Senior Director of Clinical Operations, bolstering medical and clinical leadership.
• Released software updates (version 4.4.0 and QTviewer 2.8) to enhance image processing time, user throughput, clinical efficiency, and diagnostic accuracy.

Negatives

• Reported an increased net loss of $4.0 million in Q2 2025, compared to $1.2 million in Q2 2024, primarily due to non-cash changes in fair value of warrant and earnout liabilities.
• Gross margin slightly declined to 50% in Q2 2025 from 51% in Q2 2024 due to variability in weighted average cost of inventory.
• Net cash used in operating activities increased to $1.5 million in Q2 2025 from $1.0 million in Q2 2024, indicating higher cash burn from operations.

Risks

• Ability to sell and deploy the QT Imaging Breast Acoustic CT Scanner.
• Ability to extend product offerings into new areas or products.
• Ability to commercialize technology.
• Unexpected occurrences that deter the full documentation and bring-to-market plan for products.
• Trends and fluctuations in the industry.
• Changes in demand and purchasing volume of customers.
• Unpredictability of suppliers.
• Ability to attract and retain qualified personnel and the ability to move product sales to production levels.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Uncertainty of projected financial information.
• Delays caused by factors outside of control.
• Changes in the ability to successfully receive purchase orders and generate revenue under existing contracts with partners and distributors.
• Ability to realize the benefits of strategic partnerships.
• Identified material weakness in internal controls over financial reporting (including the timeline to remediate).
• Rollout of the business and the timing of expected business milestones.
• Effects of competition on future business.
• Ability to obtain and access financing in the future.
• Ability to pay debt obligations as they come due.

Future Outlook

The company reiterates its plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners) and $27 million in revenue in 2026 (shipment of 60 scanners), in accordance with committed orders from its distribution partner, NXC Imaging. It is also accelerating its transformation into a precision imaging AI company with the development of the 'QTI Cloud Platform,' a tiered Software as a Service (SaaS) delivery model expected to provide recurring revenues and AI-driven tools for breast health.

Management Comments

• "We are pleased to report that the strong business momentum from the first quarter carried through Q2, and in many ways, we are even more energized by the significant opportunities ahead."
• "QT Imaging is rapidly evolving from a scanner company into a scalable imaging platform combining proprietary hardware, advanced image reconstruction software, and AI-powered clinical decision tools to address the growing need for precision in breast health."
• "Our goal is not only to drive greater user adoption of our proprietary, state-of-the-art scanner technology, but also to advance and commercialize a new generation of AI-enhanced diagnostic tools that support earlier detection, enable better categorization and staging, improve outcomes, and broaden access."
• "With eight scanners shipped in Q2 and two more in July under our USA distribution agreement with NXC Imaging, we are building the foundation for broader adoption."
• "Increasing the price of our common shares via a reverse stock split is intended to comply with the minimum share price requirement for uplisting to Nasdaq. We hope to have the support of our stockholders as we take this next pivotal step in QT Imagings growth."

Industry Context

The announcement reflects a significant trend in the medical imaging industry towards integrating artificial intelligence (AI) and software-as-a-service (SaaS) models to enhance diagnostic capabilities and create recurring revenue streams. QT Imaging's focus on radiation-free 3D breast imaging addresses a growing need for precision and safety in breast health, aligning with broader healthcare shifts towards non-invasive and patient-centric technologies. The partnership with NXC Imaging, a subsidiary of Canon Medical Systems USA, positions the company within a competitive landscape dominated by major medical device players, leveraging established distribution channels.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. However, the strategic shift towards an AI-powered SaaS platform is consistent with broader industry trends seen in other medical technology companies aiming to diversify revenue streams beyond hardware sales and enhance diagnostic accuracy through advanced software.

Management Changes

Corporate Governance

Related Party Transactions

• QT Imaging Board members fully funded $500,000 of the $700,000 net proceeds from two Private Investment in Public Entity (PIPE) investments.

Stakeholder Impact

• Shareholders: Potential for increased stock price and liquidity through Nasdaq uplisting, improved balance sheet due to warrant reclassification, and potential for future recurring revenue from the QTI Cloud Platform.
• Patients: Increased access to radiation-free 3D breast imaging technology and potential for earlier detection and improved outcomes through AI-enhanced diagnostic tools.
• Employees: Bolstered medical and clinical leadership with new appointments.
• Investment Professionals: Provides clear financial metrics, strategic direction, and a path to improved market visibility and financial stability.

Next Steps

• Hold the Annual Meeting of stockholders virtually on August 19, 2025, to vote on increasing the price of common shares via a reverse stock split for Nasdaq uplisting.
• Continue building the foundation for broader adoption by shipping QT Imaging Breast Acoustic CT scanners under the USA distribution agreement with NXC Imaging.
• Advance and commercialize the new generation of AI-enhanced diagnostic tools through the QTI Cloud Platform.
• Address and remediate the identified material weakness in internal controls over financial reporting.

Key Dates

Recommendation

The company demonstrates robust revenue growth, exceeding 100% year-over-year, and is on track to meet its ambitious 2025 revenue targets. Strategic initiatives, including the development of an AI-powered cloud platform for recurring revenue and the pursuit of a Nasdaq uplisting, signal significant future growth potential and improved market visibility. The reclassification of warrant liabilities to equity strengthens the balance sheet. While net loss increased, it was primarily due to non-cash accounting adjustments, and Adjusted EBITDA improved. The increased cash position post-quarter end further supports operational stability. These factors suggest a positive trajectory for the company, making it an attractive investment.

Keywords

Breast Imaging, Medical Device, AI Diagnostics, SaaS Platform, Acoustic CT, Healthcare Technology, Financial Results, Nasdaq Uplisting, QTIH, Radiology